Co-localization of transforming growth factor beta 2 with alpha 1(I) procollagen mRNA in tissue sections of patients with systemic sclerosis.

M Kulozik; A Hogg; B Lankat-Buttgereit; T Krieg

doi:10.1172/JCI114793

Dermatologische Klinik und Poliklinik, Ludwig-Maximilians-Universität München, Federal Republic of Germany.

Find articles by Kulozik, M. in: PubMed | Google Scholar

Dermatologische Klinik und Poliklinik, Ludwig-Maximilians-Universität München, Federal Republic of Germany.

Find articles by Hogg, A. in: PubMed | Google Scholar

Dermatologische Klinik und Poliklinik, Ludwig-Maximilians-Universität München, Federal Republic of Germany.

Find articles by Lankat-Buttgereit, B. in: PubMed | Google Scholar

Dermatologische Klinik und Poliklinik, Ludwig-Maximilians-Universität München, Federal Republic of Germany.

Find articles by Krieg, T. in: PubMed | Google Scholar

Published in Volume 86, Issue 3 on September 1, 1990
J Clin Invest. 1990;86(3):917–922. https://doi.org/10.1172/JCI114793.
© 1990 The American Society for Clinical Investigation

Published September 1, 1990 - Version history

The role of transforming growth factor beta 2 (TGF-beta 2) in the pathogenesis of systemic sclerosis (SSc) was investigated by in situ hybridization of skin biopsies from six patients with SSc. Two patients with acute systemic lupus erythematosis (SLE), one with acute dermatomyositis (DM), and three healthy individuals were used as controls. TGF-beta 2 mRNA was found to be co-localized with pro alpha 1(I) collagen expression around dermal blood vessels in all patients with the inflammatory stage of SSc, whereas there was no expression of either gene in the dermis of patients in the fibrotic stage, the SLE patients or the normal controls. These findings provide evidence that TGF-beta 2 released by inflammatory cells around blood vessels may play a role in mediating the collagen gene disregulation in fibrosis.

Images.